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The presence of progesterone receptors (PR) in the human placenta has been demonstrated using the reverse
transcriptase–polymerase chain reaction technique. It was observed that the amount of PR in the human
placenta is less during late gestation. Electrophoretic mobility shift assays with nuclear extract isolated from
the first trimester and term placenta revealed three complexes when incubated with [32P]dCTP-labelled
progesterone response element, and, in competition with unlabelled progesterone response element, the
formation of all three complexes was inhibited. When supershift analysis of these complexes was carried out
using antibodies which cross-react with both the A and B types of the PR or only with the B type receptor,
only the A-form of PR was detected in the human placenta.
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Introduction
The two most important steroid hormones produced by the
human placenta are oestradiol and progesterone, the concentra-
tions of which continuously increase throughout the course of
pregnancy. The quantity of progesterone produced by the
human placenta can be as much as 250–600 mg per day during
late gestation (Solomon, 1994). The intracellular concentra-
tion of progesterone within the placenta is estimated to be
~7 µmol/l (Khan-Dawood and Dawood, 1984). Although
progesterone is known to be indispensable for the maintenance
of pregnancy, its exact role during pregnancy is not completely
understood. It is known that progesterone is crucial for keeping
the uterus in a quiescent state in order to prevent premature
onset of labour. Apart from the uterus, the placenta itself has
been suggested to be a target tissue for the action of progester-
one. However, there has been no conclusive evidence for the
presence of progesterone receptors (PR) in the human placenta
(McCormick et al., 1981; Younes et al., 1981; Rivera and
Cano, 1989; Padayachi et al., 1990; Karalis et al., 1996). This
has mainly been due to the techniques employed, particularly
the nuclear exchange assay, the application of which to human
placenta poses considerable problems because of the high
endogenous concentration of progesterone. We have demon-
strated the expression of PR mRNA in the first trimester human
placenta (FTHP) using the technique of reverse transcriptase–
polymerase chain reaction (RT–PCR) (Shanker et al., 1997).
Subsequently (Rossmanith et al., 1997) it has also been
reported that the presence of PR in the human placenta using
the technique of immunocytochemistry as well as RT–PCR at
all stages of development although no binding could be
demonstrated with 3H-labelled steroids. In the present paper,
we report the results of our studies which provide additional
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evidence to establish the presence of PR protein in the
human placenta.
Materials and methods
Materials
Modifying enzymes and PCR reagents were obtained from Life
Technologies Inc., Gaithesburg, MD, USA. Enhanced Chemi-
luminescence (ECL) detection reagents and Hybond nitrocellulose
were obtained from Amersham, Life Sciences Ltd, Buckingham, UK.
[α-32P]dCTP was obtained from Du Pont. Secondary antibody–
horseradish peroxidase (HRP) conjugate and other routine chemicals
were obtained from Sigma, St Louis, MO, USA. hPRA-3, which
recognizes both PR types A and B, was obtained as a gift from Prof.
Satyaswaroop, University of Pennsylvania, Philadelphia, PA, USA,
and KC 146 which recognizes only PR type B, was generously
provided by Prof. Geoffrey Greene, University of Chicago, Chicago,
IL, USA.
RT–PCR
The procedures employed for the collection of human placenta,
isolation of RNA, RT–PCR, and the sequences of the primers used
have been described earlier (Shanker et al., 1997). Primers specific
for human PR were designed based on the published sequence of the
human PR cDNA in order to amplify the region corresponding to
amino acids 730–840 (ligand binding domain). The forward primer
used was 59 GGCGGATCCGTCAAGTGGTCTAAATCATTG 39 and
the reverse primer used was 59 GGCGAATTCCTGGGTTTGACTT-
CGTAGCCC 39. The expected size of amplification with the set of
primers used is 351 bp. To rule out the possibility that the amplification
is due to contamination from uterine tissue with which placenta is
closely associated and which is also a rich source for PR, every batch
of RNA isolated from placenta was screened for the presence of
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message for the uterine protein PP14 using specific primers. It is now
well established that PP14 is an exclusively uterine protein. It should
also be noted that the PP14 message could be detected even when
RNA was diluted 1000-fold, and in all our RT–PCR reactions to
monitor PR we employed undiluted RNA without detecting PP14
message, thus establishing that the observed amplification is indeed
due to presence of PR in placenta and not due to uterine tissue
contamination. Two micrograms of first trimester, or 6 µg of term,
placental total RNA was used for RT–PCR; 10% of the RT reaction
product was used for PCR in the case of first trimester placenta,
while 20% was used in the case of term placenta.
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts from human placenta were prepared according to
established methods (Gorski et al., 1986) with some modifications in
the procedure of salt extraction. All procedures were carried out in
the cold, and all solutions, tubes and centrifuges were chilled to
0°C. When included, phenylmethylsulphonyl fluoride (PMSF) and
dithiothreitol (DTT) were added to the buffers just prior to use. Five
grams of human first trimester or term placental minces were gently
homogenized in 10 ml homogenization buffer [10 mM HEPES–KOH
(pH 7.6), 25 mmol/l KCl, 0.5 mmol/l spermidine, 1 mmol/l EDTA,
2 mol/l sucrose, 10% glycerol] using a motor-driven glass-teflon
homogenizer until most of the cells were broken, leaving the nuclei
intact. The homogenate was diluted to 28.3 ml with homogenization
buffer, layered on a 10 ml cushion of the same buffer and centrifuged
at 76 000 g for 30 min at –2°C in an SW28 rotor. The nuclear pellet
obtained was resuspended in 1.7 ml of nuclear lysis buffer [10 mM
HEPES-KOH (pH 7.6), 100 mmol/l KCl, 3 mmol/l MgCl2, 0.1 mmol/
l EDTA. 1 mmol/l DTT. 0.1 mmol/l PMSF, 10% glycerol] and KCl
was added to a final concentration of 0.5 mol/l. The suspension was
kept on ice for 30 min with frequent vortexing to extract DNA
binding proteins. Following this, the suspension was centrifuged at
12 000 g for 10 min at 0°C and the supernatant was dialysed against
two changes of dialysis buffer [25 mM HEPES–KOH (pH 7.6),
40 mmol/l KCl, 0.1 mmol/l EDTA, 1 mmol/l DTT,10% glycerol]
overnight. The dialysate was centrifuged at 12 000 g for 10 min at
0°C and the supernatant was frozen in small aliquots by placing in
liquid nitrogen and stored at –70°C until further use. EMSA was
performed as described (Klein-Hitpass et al., 1991). Typical binding
reactions contained (20 µl volume): 100–200 pg (4–53104 cpm)
progestin response element (PRE) oligonucleotide labelled with
[α-32P]dCTP and Klenow DNA polymerase, 250 ng poly [dIdC.dIdC,
20 µg (FTHP) or 50 µg (term placenta) nuclear extract, 25 mmol/l
HEPES–KOH pH 7.6], 60 mmol/l KCl, 10% (w/v) glycerol, 2.5%
(w/v) Ficoll 400, 1 mmol/l MgCl2, 2 mmol/l DTT, 0.15 mmol/l
EDTA and 0.05 mmol/l EGTA. Binding reactions were carried out
at room temperature for 20 min, separated in 4.5% polyacrylamide
gels, dried and autoradiographed. For antibody-mediated supershift,
binding reaction mixtures were incubated for a further 20 min in the
presence of 1 µg of either of the two monoclonal antibodies to the
human PR, hPRa-3 or KC 146. The PRE oligonucleotide used as
probe and competitor was obtained by annealing the two
complementary strands 59-ggttAAAGTCAGAACACAGTGTTCTG-
ATCAA-39 and 59-ggttTTGATCAGAACACTGTGTTCTGACTTT-
39. The 59 ‘ggtt’ overhangs so obtained were used as templates to
radiolabel the duplex by end-filling with Klenow polymerase in the
presence of [α-32P]dCTP. Protein content in the nuclear extracts was
estimated according to established methods (Lowry et al., 1951)
using bovine serum albumin as the standard.
Western blot analysis
Nuclear extracts (200 µg protein) prepared from first trimester or
term placenta were electrophoresed on 10% sodium dodecyl
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Figure 1. Demonstration of expression of progesterone receptor
(PR) mRNA in first trimester human placenta (FTHP) and term
human placenta by reverse transcriptase–polymerase chain reaction
(RT–PCR). Total RNA was isolated and reverse transcribed using
Superscript preamplification (Gibco-BRL, Grand Island, NY, USA).
First strand cDNA was used to carry out PCR as described in the
text. PCR products were directly electrophoresed on a 1.5% agarose
gel and stained with ethidium bromide. The positions of DNA
markers (size in bp) are shown at the right of lane 4. Lane 1: no
template control; lane 2: No RT control; lane 3: RT–PCR of FTHP
RNA; lane 4: RT–PCR of term placental RNA. A 351 bp amplified
product (marked by the arrow) was observed in lanes 3 and 4 but
not in lanes 1 and 2.
sulphate–polyacrylamide gel electrophoresis and were transferred to
nitrocellulose as described (Towbin et al., 1979). After blocking the
non-specific binding sites by incubating the membrane with 5% fat-
free milk, it was incubated with hPRa-3 (4 µg/ml), followed by
incubation with anti-mouse IgG–HRP conjugate. Antigen–antibody
complex was detected using enhanced chemiluminescence Western
blotting reagents (Amersham).
Results
Expression of PR mRNA in human placenta
The RT–PCR analysis for PR mRNA using first trimester and
term human placental RNA is presented in Figure 1. An
amplified DNA fragment of the size 351 bp was seen in both
the first trimester as well as term placental RNA. However,
the quantity of PCR product formed was significantly less in
term placenta than in FTHP (compare lanes 3 and 4, Figure
1), despite the fact that the quantity of RNA and first strand
cDNA used for performing RT–PCR was twice the quantity
in the case of term placenta as it was in the case of FTHP.
Demonstration of PR protein in the human placenta
Since the PR mRNA was detectable only by RT–PCR but not
by Northern analysis (Shanker et al., 1997), we felt that it was
essential to demonstrate the presence of the protein. The PR
is a DNA binding protein belonging to the family of steroid/
thyroid/retinoid receptors and hence EMSA can be employed
to demonstrate the presence of PR protein. It can be seen from
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Figure 2. Electrophoretic gel mobility shift analysis (EMSA) of
progestin response element (PRE)-binding proteins in human
placental nuclear extracts. Three complexes (designated as
complexes 1, 2 and 3) with retarded mobility were observed
(lane 2). Formation of complexes was abolished by carrying out the
EMSA in the presence of 10- or 20-fold excess (lanes 3 and 4) of
non-radiolabelled PRE. All three complexes were formed when
EMSA were carried out in the presence of 50- or 100-fold excess
(lanes 5 and 6) of an irrelevant oligonucleotide, retinoic acid
response element (RARE). Lane 1: free probe; lane 2: first
trimester human placenta nuclear extract; lane 3: 10-fold excess of
non-radiolabelled PRE; lane 4: 20-fold excess of non-radiolabelled
PRE; lane 5: 50-fold excess of non-radiolabelled RARE; lane 6:
100-fold excess of non-radiolabelled RARE.
the results presented in Figure 2 that following incubation of
placental nuclear extracts with the 32P-labelled PRE oligonucle-
otide, three retarded complexes were detected (Figure 2, lane
2, signals numbered 1, 2 and 3). All three complexes appeared
to be specific in nature since the formation of each complex
could be competitively inhibited by the binding reaction in the
presence of excess unlabelled PRE (Figure 2, lanes 3 and 4).
However, inclusion of an excess of an irrelevant oligonucleo-
tide (retinoic acid response element, RARE) in the binding
reaction had no effect on the number or the intensity of the
complexes formed (Figure 2, lanes 5 and 6).
In order to identify which of the three complexes contained
PR, we did supershift analysis with a monoclonal antibody to
the human PR, hPRa-3, which is known to recognize both the
forms of PR, i.e. PR-A and PR-B (Clarke et al., 1987). It can
be seen from Figure 3 that only complex 1 was supershifted
by the antibody (signal numbered 1, lane 3) suggesting that it
was complex 1 which contained PR. This supershift was not
observed (lane 4) with an irrelevant antibody, C1C5 (which
recognizes retinol binding protein), thus establishing the speci-
ficity of the antibody used. Interestingly incubation with KC
146, an antibody which recognized only the B form of PR,
did not result in any supershift of the complex (lane 5). The
supershifted complex numbered 2 in lane 7 of Figure 3 could
represent other known or unknown members of the steroid
receptor superfamily which bind to the same DNA sequence,
PRE.
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Figure 3. Supershift analysis to establish the identity of the
complex containing progesterone receptor (PR) and to identify the
isoforms of PR in human placenta. Following the binding reaction,
samples were incubated with antibodies hPRa-3, C1C5, or KC 146
prior to electrophoresis. Supershifting of complex 1 was observed
with hPRa-3 (lane 3) but not with the irrelevant antibody, C1C5
(lane 4) or with the PR-B-specific antibody, KC 146 (lane 5).
Incubation with KC 146 resulted in a supershift of the PR-
containing complex (signals numbered 1and 2) in T47D cell
extracts (lane 7) which were used as positive control. Lane 1: free
probe; lane 2: control placental extract; lane 3: placental extract
incubated with hPRa-3; lane 4: placental extract incubated with
C1C5; lane 5: placental extract incubated with KC146; lane 6:
control T47D cell extract; lane 7: T47D cell extract incubated with
KC146.
Figure 4. Western blot analysis of first trimester human placenta
(FTHP) and term placental nuclear extracts. Nuclear extracts were
prepared as described, subjected to sodium dodecyl sulphate–
polyacrylamide gel electrophoresis, electrophoretically transferred
to nitrocellulose and subsequently processed for Western blot
analysis. The positions of the molecular weight markers are
indicated at the right of lane 2. The arrow at the left indicates the
position of the 82 kDa human PR-A. No signals were observed in
the negative control probed with normal mouse serum (data not
shown). Lane 1: FTHP; lane 2: term placenta.
Western blot analysis carried out with hPRa-3 revealed the
presence of an 82 kDa species corresponding to PR-A (Figure
4) and this value agrees with the size previously reported (Feil
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et al., 1988). A 68 kDa species was also observed, which is
likely to be a proteolytic product of PR, as has been observed
in other tissues on a Western blot (Feil et al., 1988). The
intensity of both the signals was significantly reduced when
the antibody was preabsorbed with excess of placental nuclear
extract (results not shown) thus establishing the specificity of
the antibody employed. It should also be noted that the quantity
of PR, as judged by the intensity of the signal, was significantly
less with term placental nuclear extract than with FTHP, as
can be seen from Figure 4, which agrees very well with the
RNA concentrations (Figure 1). Densitometric scanning of the
autoradiogram shown in Figure 4 revealed that there was a
70% decrease in the level of the 82 kDa signal in term placenta
as compared to FTHP.
B form of PR is not detectable in the human placenta
It can be seen from results presented in Figure 4 that only the
82 kDa size PR-A species was detectable in the placental
nuclear extract. In contrast, PR-B, which has an apparent
molecular weight of 116–120 kDa, was not detected by the
Western blot. In order to confirm this, supershift analysis
was performed with another monoclonal antibody, KC 146,
which recognizes only the B form of PR (Press and Greene,
1988). It can be seen from results presented in Figure 3 (lane
5) that unlike the result with the hPRa-3, supershift of the PR-
containing complex (complex I) was not observed when
incubated with KC 146. However, supershift of the PR-
containing complex from T47D cell nuclear extract, which is
known to contain both the forms of PR, was observed with
KC 146. Results of both these experiments suggested that the
B form of PR was not detectable in the human placenta.
Discussion
Apart from the uterus, it has been suggested that progesterone
might also exert its effects on the placenta and thereby regulate
placental function. In fact, recent reports describing the effects
of progesterone on the expression of chorionic gonadotrophin
(CG) α and β subunit genes in the human placenta (Rao et al.,
1995) and corticotrophin releasing hormone (CRH) gene in
human trophoblast cell cultures (Karalis et al., 1996) provide
sufficient evidence to suggest that placenta itself can be a
target tissue for the action of progesterone, though it has not
been possible to accept this suggestion with certainity due to
several conflicting reports in the literature (McCormick et al.,
1981; Younes et al., 1981; Rivera and Cano, 1989; Padayachi
et al., 1990; Karalis et al., 1996). Although it has been reported
(Karalis et al., 1996) that human PR immunoreactivity could
not be detected in trophoblast cells isolated from term
placenta, studies (Rossmanith et al., 1997) as well as our own
provide definitive evidence for the presence of PR in the
human placenta. We have recently established, using RT–PCR,
the expression of PR mRNA in the first trimester human
placenta. This conclusion was based on the results obtained
by Southern hybridization, restriction mapping and DNA
sequence analysis of the PCR amplified fragment (Shanker
et al., 1997). We have provided additional evidence in the
present study that, in addition to the mRNA, PR protein is
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also present in the human placenta during early as well as late
gestation using gel retardation assays and Western blot analysis.
Our ability to detect PR message only by RT–PCR and not
by Northern analysis could be due to the fact that the transcript
concentration of PR could be very low or unstable. It should
be added that the RT–PCR has the added advantage of several
cycles of amplification and several cases of messages not
detectable by Northern analysis but detectable by PCR are
known (Ma et al., 1994). It is also possible that PR expression
could be under a translational control so that its level of
expression is adequate enough for detection by Western blot
analysis. The failure to detect PR protein by Western blot
(Karalis et al., 1996) is perhaps due to the limitation in the
quantity of protein loaded, source material or mode of detection.
While Karalis et al. have used cytosolic extracts prepared from
cultured trophoblast cells and 125I-labelled protein A detection
for their Western blot analysis, we have employed nuclear
extracts (which are known to be enriched for nuclear receptor)
prepared from placental villous tissue and enhanced chemilu-
minescence detection, which is a highly sensitive mode of
detection, for our Western blot analyses.
The concentration of PR mRNA is much higher in FTHP
than in term placenta (Figure 1) which is also reflected in the
protein concentration as judged by Western blot analysis
(Figure 4) or EMSA (data not shown). The extremely low
concentration of PR in the term placenta could be of signi-
ficance in the initiation of labour. In most mammals (except
primates), the end of gestation is associated with a fall in
maternal progesterone concentration which contributes to the
initiation of labour. In humans and other primates, labour is
initiated, although there is no fall in the concentration of
progesterone. This suggests that a decline in progesterone
action in late gestation, without an actual fall in the concentra-
tion of the hormone, could be an important component of
initiation of labour in women. Progesterone inactivation by a
specific binding protein (Westphat et al., 1997), or by a local
antiprogestin (Casey and Macdonald, 1993), or by a change
in PR concentrations (Khan-Dawood and Dawood, 1984)
during late pregnancy has been suggested but not demonstrated.
Recently it has been proposed (Karalis et al., 1996) that
cortisol might be the local antiprogestin which blocks the
action of progesterone to initiate labour. It has been suggested
that in the human placenta, progesterone might bring about its
actions by binding to the glucocorticoid receptor in the absence
of PR; cortisol would compete for the glucocorticoid receptor
with progesterone, thus blocking the action of progesterone
resulting in the initiation of labour. However, our results
demonstrate that the PR indeed are present even during late
gestation, though there is a significant decline in the placental
PR concentrations. Consequently, it is only justified to consider
the involvement of the PR to a great extent in initiation of
labour in addition to the possible involvement of glucocorticoid
receptors as proposed (Karalis et al., 1996). In addition, results
obtained in our laboratory have demonstrated that ZK 98299,
an antiprogestin known not to have any anti-glucocorticoid
activity (Koper et al., 1997) (unlike the more commonly used
antiprogestin RU 486 which binds to glucocorticoid receptor),
inhibits the expression of CG α and β subunit genes (Prasad,
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1993), and regulates progesterone synthesis (Shanker and Rao,
1997) in the human placenta, suggesting the presence of
functional PR in the human placenta. Our results demonstrate
a decline in PR concentrations during late pregnancy and this
agrees well with other suggestions (Khan-Dawood and Dawood
1984), who proposed that the decrease in PR at the end of
gestation might be a factor contributing to the onset of labor.
PR is a ligand-inducible transcription factor belonging to
the family of steroid/thyroid/retinoic acid receptors. It regulates
gene expression by binding to PRE on the DNA located
upstream of progesterone-responsive genes, upon activation
by the binding of progesterone. The human PR exists as two
major forms: PR-B is the full length receptor and is 933 amino
acids long; PR-A lacks 164 residues from the N-terminus
(Weigel, 1996). Our data suggest that only the A form of PR
is detectable in the human placenta. The results obtained using
nuclear extracts prepared from T47D cancer cells (known to
express PR), which were used as a positive control in the gel
retardation assays establish that the antibody used is specific.
Besides, this antibody is a well characterised one and is
reported to be specific for PR (Clarke et al., 1987). It is well
established that PR-A is a ligand-dependent, trans-dominant
repressor of the activity of glucocorticoid, mineralocorticoid
and androgen receptors, as well as that of PR-B (Tung et al.,
1993; Vegeto et al., 1993). Studies (Tung et al., 1993) reveal
that when PR-B alone is present the ligands such as RU486,
which are regarded as antagonists, behave as agonists. It is
pertinent to note in this connection that our earlier studies
(Shanker and Rao, 1997) revealed that while RU 486 stimulates
progesterone synthesis in FTHP, it inhibits in the term placenta.
Using anti-progesterone antibodies specific for B type as well
as those that recognize both A and B type, It has been
demonstrated (Wang et al., 1998) that by immunohisto-
chemistry that both types of receptors could be detected in
glandular and stromal nuclei during the proliferative phase but
only in stromal nuclei during the secretory phase and early
pregnancy. Of importance to the present discussion is the
observation that the predominant type of PR in the stromal
nuclei during the secretory phase and early pregnancy is the
A type, also observed by us. Additional support for the
possibility that only the A form is predominantly present in
certain situations comes from other studies (Viville et al.,
1997) who have reported that A type dominated over B type
in leiomyomata. There is only other report claiming that PR-
B is not detectable (Boyd-Leinen et al., 1982), who reported
the absence of PR-B in the oviduct of aged non-laying hens.
It is suggested (Kastner et al., 1990) that the differential
expression of hPR forms A and B from their cognate promoters
generates a system of tissue-specific regulation of progesterone
action. However, the possibility that our failure to detect the
PR-B in the human placenta in the present study could be due
to the extremely low level of expression, which may be below
the limits of detection methods employed in the study, cannot
be ruled out. It has been well documented that the ratio of
PR-A to -B determines the genetic response of a target cell to
progesterone. Considering this, as well as our results on the
differential action of RU 486 in placenta, it is possible that
the presence of PR-A stimulates progesterone production
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during early pregnancy, whereas, with the progression of
pregnancy, in the presence of PR-A and possible presence of
PR-B (not detectable by us by the present methods) RU 486
inhibits progesterone production. In a tissue such as placenta,
where the ratio of PR isoforms appears to be highly in favour
of PR-A, the in-vivo scenario could be very complex due to
the trans-dominant repressor function of PR-A.
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